Roberto Pili, MD, a nationally recognized expert in prostate, renal, and bladder cancers, has joined the Indiana University (IU) Melvin and Bren Simon Cancer Center.
Dr. Pili is the Robert Wallace Miller Professor of Oncology at the Indiana University School of Medicine and Researcher at the IU Simon Cancer Center. In his new position, Dr. Pili will also be Director of the Genitourinary Research Program at the Cancer Center. In addition, Dr. Pili will serve as the Medical Director of the Genitourinary Clinical Program at the IU Health Simon Cancer Center. The genitourinary program supports treatment for prostate, bladder, kidney, testicular, and penile cancers.
The Genitourinary Research Program’s scientists will collaborate with researchers at the Purdue University Center for Cancer Research. The developing program will be co-led by Timothy Ratliff, PhD, the Robert Wallace Miller Director of the Purdue Cancer Center.
On the clinical side, Dr. Pili said his goal is to focus on drug resistance in those genitourinary cancers, providing new options for those patients.
Most recently, Dr. Pili was Professor of Oncology, Chief of the Genitourinary Section, and Leader of the Genitourinary Program at the Roswell Park Cancer Institute.
Dr. Pili earned his medical degree from the Catholic University School of Medicine, in Rome, Italy. He did his residency training in internal medicine at Montefiore Medical Center, completed a clinical research fellowship in medical oncology at Johns Hopkins University, and a second fellowship at the National Institute on Aging, National Institutes of Health. His laboratory research focuses on the development of novel therapeutic agents, including epigenetic agents such as histone deacetylase inhibitors and understanding their immunomodulatory effects. He also conducts phase I/II clinical trials of novel agents for the treatment of genitourinary malignancies.
Dr. Pili is a member of ASCO and the American Association for Cancer Research. He serves as a reviewer for study sections of the National Cancer Institute and the Department of Defense. ■